Longitudinal study of susceptibilities of species of the Bacteroides fragilis group to five antimicrobial agents in three medical centers.
A total of 579 clinical isolates of the Bacteroides fragilis group collected from three Canadian hospitals were tested for susceptibility to five antimicrobial agents by using an agar dilution method. During the 4-year survey, isolates from intra-abdominal infections were collected from the following sites: abdominal abscesses (48%), peritoneal fluid (39%), blood (10%), and bile (3%). B. fragilis was the most prevalent species (35.4%), followed by B. thetaiotaomicron (19.2%), B. ovatus (15.9%), and B. vulgatus (11%). No metronidazole- or imipenem-resistant strains were found during the survey. Resistance profiles varied among the different species tested: 7.8, 2.9, and 7.3% of B. fragilis strains (n = 205) and 68.1, 17.2, and 9.4% of non-B. fragilis strains (n = 373) were resistant to cefotetan, cefoxitin, and clindamycin, respectively. B. fragilis and B. vulgatus demonstrated lower resistance rates than B. thetaiotaomicron, B. ovatus, B. distasonis, and B. caccae. During the study, rates of resistance to cefotetan and clindamycin fluctuated but rates of resistance to cefoxitin increased, particularly at one center. These data indicate a need to determine the susceptibility patterns of the B. fragilis group periodically at each hospital.
Hôpital Saint-Luc, Montreal, Quebec, Canada.
P
P
Turgeon
V
V
Turgeon
M
M
Gourdeau
J
J
Dubois
F
F
Lamothe
D001441:Bacteroides fragilis / Q000187:drug effects* / Q000302:isolation & purification; D015313:Cefotetan / Q000494:pharmacology; D002440:Cefoxitin / Q000494:pharmacology; D002981:Clindamycin / Q000494:pharmacology; D004352:Drug Resistance, Microbial; D015378:Imipenem / Q000494:pharmacology; D008137:Longitudinal Studies; D008795:Metronidazole / Q000494:pharmacology; D008826:Microbial Sensitivity Tests
D008795:Metronidazole; D002981:Clindamycin; D015313:Cefotetan; D002440:Cefoxitin; D015378:Imipenem